- AimedBio’s novel brain tumor therapeutics, AMB302, was selected as a government-initiated drug development program by the Korean Drug Development Fund (KDDF).
- AMB302 is a first-in-class ADC therapeutics targeting a brain tumor specific fusion
oncogene.
- AimedBio
has confirmed significant tumor killing effect of AMB302 candidate.
- AimedBio utilizes patients’ genetic/clinical data and patient-derived samples in the antibody development process, resulting in higher probability of clinical success.